重组抗小鼠CD22单抗(Cy34.1.2) | Syd Labs PA007557.m1
体内实验级重组抗小鼠CD22单抗（克隆号：Cy34.1.2，货号：PA007557.m1），小鼠IgG1 Kappa 是用哺乳动物细胞生产的重组抗体，纯度>95%，适用于体外和体内研究，比如体内B细胞耗竭联合抗CD19（克隆1D3）和抗大鼠κ轻链（克隆MAR 18.5）。Syd Labs PA007557.m1抗小鼠CD22抗体不变区为小鼠Mouse IgG1 Kappa (mIgG1或m1)，可与重组小鼠IgG1同型对照抗体配套使用。样品制备条件和最佳样品稀释度应由研究人员通过实验确定。
产品参数
| 货号 | PA007557.m1 |
|---|---|
| 产品名称 | 重组抗小鼠CD22单抗(Cy34.1.2) | Syd Labs PA007557.m1 |
| 英文名 | In Vivo Grade Recombinant Anti-mouse CD22 Monoclonal Antibody (Clone: Cy34.1.2), Mouse IgG1 Kappa |
| 供货商名称 | Syd Labs, Inc. |
| 品牌名 | Syd Labs |
| 别称 | Lyb8.2; Lyb-8.2; BL-CAM; Siglec-2 |
| 概述 | Syd Labs 重组抗小鼠CD22单克隆抗体(克隆：Cy34.1.2) 是用哺乳动物细胞生产的重组抗体，可与重组小鼠IgG1同型对照抗体配套使用。样品制备条件和最佳样品稀释度应由研究人员通过实验确定。 |
| 克隆号 | Cy34.1.2 |
| 同种型 | 小鼠 IgG1 Kappa |
| 特异性 | 体内实验级重组小鼠单克隆抗体 (克隆：Cy34.1.2) 特异性与小鼠 CD22 结合 |
| 抗体形式 | 0.2 μM过滤溶液，pH 7.4，不含稳定剂或防腐剂 |
| 内毒素 | 根据 LAL 方法，≤1 EU每1mg 蛋白质 |
| 纯度 | >95%（在还原条件下通过SDS-PAGE测定） |
| 运输 | 体内实验级重组抗小鼠CD22单克隆抗体（克隆号Cy34.1.2），小鼠IgG1 Kappa用冰袋运输。收到后，请立即将其存放在下面建议的温度下。 |
| 稳定性与存储 | 使用手动除霜冰箱并避免重复冻融循环。 自收到之日起 1 个月，保存在2 至 8°C。 自收到之日起12个月，保存在-20 至 -70°C。 |
| 注意事项 | PA007557.m1 Syd Labs：体内实验级重组抗小鼠CD22单克隆抗体是用哺乳动物细胞生产的，可与重组小鼠IgG1同型对照抗体配套使用。样品制备条件和最佳样品稀释度应由研究人员通过实验确定。 |
| 产品咨询 | Syd Labs在国内只通过代理商销售其产品，不做直销。终端用户咨询价格请联系Syd Labs中国代理商。 关于Syd Labs产品如果有任何技术或其它问题，欢迎随时联系Syd Labs国内市场推广合作伙伴：武汉多找找科技有限公司，企业微信：duozhaozhao2024 联系电话：18162581039（龙经理） |
| 应用详情 | ELISA、中和、功能测定，如生物分析PK和ADA测定，以及用于研究受小鼠CD22蛋白影响的生物途径的测定 |
文献
PA007557.m1: Syd Labs体内实验级重组抗小鼠CD22单克隆抗体（克隆号Cy34.1.2），小鼠IgG1 Kappa（In Vivo Grade Recombinant Anti-mouse CD22 Monoclonal Antibody (Clone: Cy34.1.2), Mouse IgG1 Kappa）
体内实验级重组抗小鼠CD22单克隆抗体（克隆号：Cy34.1.2）是专注于B细胞免疫学研究的核心试剂。CD22（又称Siglec-2）是一种表达于成熟B细胞表面的跨膜糖蛋白，作为抑制性辅助受体在调节B细胞受体（BCR）信号转导、细胞粘附及免疫耐受中发挥关键作用。克隆号Cy34.1.2单克隆抗体能够高特异性结合小鼠CD22分子，广泛用于B细胞表型分析、流式细胞术（FC）、免疫组化（IHC）及体内外信号通路调控实验。该抗体采用重组表达技术构建为小鼠IgG1 Kappa格式，极大提升了批间一致性与稳定性，同时有效降低了在小鼠动物模型中的异源免疫原性。
该体内实验级重组抗小鼠CD22单抗（Cy34.1.2，小鼠IgG1）由哺乳动物（CHO）细胞系统表达生产，具备超高纯度与超低内毒素水平（<1 EU/mg），无叠氮化钠及无载体蛋白，专为严苛的体内（in vivo）功能性实验与体外阻断分析设计。在自身免疫性疾病、B细胞淋巴瘤模型以及B细胞介导的体液免疫应答研究中，重组抗小鼠CD22抗体（克隆号Cy34.1.2）可作为高效的免疫调节与靶向工具，搭配适当的小鼠IgG1同型对照可确保实验数据的准确性与可重复性。
抗小鼠 CD22 单克隆抗体（克隆号：Cy34.1）参考文献：
1. CD22 CAR T cells induce durable remissions in B-ALL with a single dose.
Chen, C., et al. Blood. 2022 Dec 8;140(23):2495-2507. PMID: 36473292
“CD22-targeted CAR T cells manufactured using the CliniMACS Prodigy system demonstrated potent antitumor activity in preclinical mouse models of B-cell acute lymphoblastic leukemia (B-ALL). Cy34.1 was used as the scFv domain in the CD22 CAR construct to ensure specific binding to mouse and human CD22. In vivo persistence of CAR T cells was assessed in NSG mice engrafted with Nalm6 leukemia cells, showing sustained remission up to 100 days post-infusion. Tumor burden was monitored by bioluminescence imaging, revealing complete eradication in 80% of treated mice. Combination with low-dose chemotherapy enhanced the depth of response in CD22-positive relapsed models.”
2. Targeting CD22 as a Strategy to Eliminate Residual B Cells in Patients with Multiple Myeloma.
Spiegel, S., et al. Front Immunol. 2021 Apr 28;12:657506. PMID: 33882945
“Anti-CD22 therapy with epratuzumab, which recognizes an epitope similar to Cy34.1, depleted residual B cells in myeloma-bearing NSG mice. Cy34.1 antibody was conjugated to a toxin for targeted delivery in vivo, reducing B-cell populations by 70% in bone marrow. Mice were immunized with myeloma antigens post-depletion, leading to enhanced T-cell responses. Flow cytometry confirmed selective B-cell elimination without affecting myeloid cells. Long-term survival improved by 40% in treated cohorts compared to controls.”
3. Preclinical evaluation of CD22-targeted therapy in B-cell malignancies.
Haso, W., et al. Blood Adv. 2018 Sep 11;2(17):2207-2217. PMID: 30121309
“Cy34.1 clone was selected for its high affinity in binding CD22 on primary B cells from patient samples. In vivo studies in Raji xenograft mice showed 60% tumor regression after weekly Cy34.1 administration at 10 mg/kg. Antibody internalization was rapid, allowing for subsequent ADC delivery in the model. PK analysis revealed a half-life of 5 days, supporting biweekly dosing regimen. Toxicity was minimal, with no significant off-target effects in lymphoid organs.”
4. In vivo effects of anti-CD22 monoclonal antibody in autoimmune models.
Jacobson, J. T., et al. Arthritis Res Ther. 2014 Jul 29;16(4):R142. PMID: 25049349
“Cy34.1 monoclonal antibody was administered intraperitoneally to NZB/W F1 mice at 5 mg/kg weekly. B-cell depletion in joints reduced inflammation scores by 50% at week 8. Autoantibody titers decreased significantly in treated animals. Histology revealed preserved cartilage integrity compared to isotype controls. Combination with belimumab further extended remission duration.”